Treatment approaches and outcomes in plasmacytomas: Analysis using a national dataset

Gaurav Goyal, Adam C. Bartley, Shealeigh Funni, Jonathan Inselman, Nilay D. Shah, Ariela L. Marshall, Aneel A. Ashrani, Prashant Kapoor, Urshila Durani, Shahrukh K. Hashmi, Mustaqeem A. Siddiqui, Francis K. Buadi, Ronald S. Go, Robert A. Kyle, Shaji Kumar, Wilson I. Gonsalves

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52-72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.

Original languageEnglish (US)
Pages (from-to)1414-1420
Number of pages7
Issue number6
StatePublished - Jun 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment approaches and outcomes in plasmacytomas: Analysis using a national dataset'. Together they form a unique fingerprint.

Cite this